A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

NCT01662869 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

564

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: 5-Fluoruracil
DRUG: Folinic acid
DRUG: Onartuzumab
DRUG: Oxaliplatin
DRUG: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]